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Abstract
Aims: Heme oxygenase-1 (HO-1) is a cytoprotective enzyme that can be down-regulated in diabetes. Its
importance for mature endothelium has been described, but its role in proangiogenic progenitors is not well
known. We investigated the effect of HO-1 on the angiogenic potential of bone marrow-derived cells (BMDCs)
and on blood flow recovery in ischemic muscle of diabetic mice. Results: Lack of HO-1 decreased the number
of endothelial progenitor cells (Lin - CD45 - cKit-Sca-1+VEGFR-2+) in murine bone marrow, and inhibited the
angiogenic potential of cultured BMDCs, affecting their survival under oxidative stress, proliferation, migra-
tion, formation of capillaries, and paracrine proangiogenic potential. Transcriptome analysis of HO-1 - / -
BMDCs revealed the attenuated up-regulation of proangiogenic genes in response to hypoxia. Heterozygous
HO-1+/ - diabetic mice subjected to hind limb ischemia exhibited reduced local expression of vascular endo-
thelial growth factor (VEGF), placental growth factor (PlGF), stromal cell-derived factor 1 (SDF-1), VEGFR-1,
VEGFR-2, and CXCR-4. This was accompanied by impaired revascularization of ischemic muscle, despite a
strong mobilization of bone marrow-derived proangiogenic progenitors (Sca-1+CXCR-4+) into peripheral
blood. Blood flow recovery could be rescued by local injections of conditioned media harvested from BMDCs,
but not by an injection of cultured BMDCs. Innovation: This is the first report showing that HO-1 hap-
loinsufficiency impairs tissue revascularization in diabetes and that proangiogenic in situ response, not pro-
genitor cell mobilization, is important for blood flow recovery. Conclusions: HO-1 is necessary for a proper
proangiogenic function of BMDCs. A low level of HO-1 in hyperglycemic mice decreases restoration of
perfusion in ischemic muscle, which can be rescued by a local injection of conditioned media from cultured
BMDCs. Antioxid. Redox Signal. 20, 1677–1692.
Introduction
Cardiovascular diseases that directly depend on tis-sue vascularity are a major medical challenge nowadays.
Cell therapy with proangiogenic bone marrow-derived cells
(BMDCs), in numerous reports referred to as endothelial
progenitor cells (EPCs) (19), can be a promising strategy for
the stimulation of blood vessel formation, particularly in
patients who cannot be treated with surgical revasculariza-
tion (34). Regardless of monocyte-endothelial mimicry,
phenotypic heterogeneity, and still not known biological
relevance of various populations [which have raised a great
deal of controversy (53)], the cells derived from bone marrow
or from peripheral blood were shown to participate in the
formation of blood vessels in adults, mainly via paracrine
signals (45). Taking into account the possible obstacles of
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cell therapy (safety concerns, including tumor formation,
requirements for high cell numbers), the alternative cell-free
strategy to induce angiogenesis by a cocktail of growth fac-
tors secreted ex vivo by the cells would also offer a thera-
peutic potential. However, both vasculogenic activity and
release of growth factors may depend on the expression of
many pro- and antiangiogenic genes in BMDCs.
An important proangiogenic gene is Hmox1, coding for
heme oxygenase-1 (HO-1), a stress-inducible cytoprotective
enzyme (17). HO-1 degrades heme to carbon monoxide
(CO), ferrous ion, and biliverdin, which is subsequently re-
duced to bilirubin by biliverdin reductase (44). HO-1 can be
induced on injury (22), augmenting the tissue regeneration
(54). Proangiogenic properties of HO-1 were confirmed in
various research models, both in vitro and in vivo (40). Im-
portantly, HO-1 was shown to be an upstream and down-
stream mediator of vascular endothelial growth factor
(VEGF) and stromal cell-derived factor 1 (SDF-1)-induced
angiogenesis [reviewed in Dulak et al. (17)].
Although homozygous HO-1 deficiency is extremely rare
in humans, with only two cases described so far (55, 71),
there is a considerable variability in HO-1 expression in
human populations, which is caused by a polymorphism of
Hmox1 promoter (61). Moreover, although large-scale anal-
ysis did not confirm a meaningful effect of Hmox1 promoter
polymorphism on coronary artery disease or myocardial in-
farction (43), there are many clinical data indicating its in-
fluence on cardiovascular complications, at least in some
groups of patients (18, 20). Thus, the presence of less active
alleles was associated with an elevated rate of restenosis after
balloon angioplasty (23) and with a higher incidence of
coronary artery disease in type 2 diabetes (11). Moreover,
among patients with peripheral artery disease (PAD), those
with less active Hmox1 promoter had higher rates of myo-
cardial infarction, percutaneous coronary interventions, and
coronary bypass operations (16).
Noteworthy, the expression of HO-1 is down-regulated in
some pathological conditions. We and others have demon-
strated the diminished level of HO-1 in diabetic mice and rats
(14, 22) and in leukocytes of type 2 diabetic patients (1, 50).
This could contribute to cardiovascular complications com-
mon in diabetes, as the adenoviral Hmox1 gene transfer to
diabetic mice improved angiogenesis and fastened wound
healing (22). It is also known that the function of proangio-
genic precursor cells is impaired in patients with cardiovas-
cular disorders (42, 66, 67). Therefore, an inquiry into the
role of HO-1 in the activity of proangiogenic BMDCs may
provide new strategies for progenitor cell modifications that
are aimed at the improvement of their regenerative potency.
A few studies examining the significance of HO-1 in
proangiogenic progenitors have been published to date, indi-
cating that this enzyme plays an important role in progenitor cell
mobilization, homing, and endothelialization of blood vessels
(38, 57, 65, 70). However, the function of HO-1-deficient
proangiogenic precursors has not been sufficiently investigated,
and nothing is known about the significance of HO-1 down-
regulation in a more clinically relevant model, namely in
proangiogenic progenitors of haplodeficient HO-1+ / - mice.
There are also no data concerning the potential effect of dia-
betes on tissue revascularization in such animals. Therefore,
our aim was to investigate how HO-1 influences proangio-
genic activities of BMDCs in vitro and in vivo under normo-
glycemic and hyperglycemic conditions, and to check whether
the application of BMDCs or BMDC-derived conditioned
media can improve angiogenesis in diabetic HO-1+ / - mice.
Results
EPCs are less frequent in bone marrow
of HO-1 deficient mice
A comparison of the bone marrow harvested from
HO-1- / - mice with that of HO-1+ / - and HO-1+ / + littermates
demonstrated the decreased frequency of cells with pheno-
type ascribed to subpopulation of EPCs: Hoe + Lin - CD45 -
cKit - Sca-1 + VEGFR-2 + in mice lacking HO-1 (Supple-
mentary Fig. S1A; Supplementary Data are available online
at www.liebertpub.com/ars). Such cells were very rare,
constituting 0.0017% – 0.0003%, 0.0011% – 0.0003%, and
0.0007% – 0.0002% of all nucleated cells in the bone marrow
of HO-1 + / + , HO-1 + / - , and HO-1 - / - individuals, respec-
tively ( p = 0.004). Therefore, our next experiments were
performed on mononuclear BMDCs cultured under condi-
tions that promote the development of endothelial cells (24).
Cultured BMDCs are a heterogeneous population, with
80%–90% of cells incorporating acetylated low-density li-
poprotein (acLDL) and binding Bandeiraea simplicifolia
isolectin (BS1) (Supplementary Fig. S1B, C), which are ca-
pable of forming capillary-like structures after seeding on
Matrigel (Supplementary Fig. S1D). Flow cytometry phe-
notyping revealed that, regardless of HO-1 genotype, the
BMDC populations contained a similar proportion of cul-
tured cells expressing endothelial or hematopoietic markers,
such as CD31, VEGFR-2 (KDR), Tie2, CD105, Sca-1, and
CD45, with a slightly lower fraction of CD34 + subset in
HO-1 + / - and HO-1 - / - cultures (Supplementary Fig. S1E).
During the 9-days of culture, the population became enriched
in the CD45 - cells co-expressing Sca-1 and VEGFR-2 by
400–500-fold (data not shown).
HO-1 deficiency affects apoptosis, proliferation,
and migration of BMDCs
According to expectations, no HO-1 protein was detected
in HO-1 - / - BMDCs. The concentration of HO-1 in
Innovation
Heme oxygenase-1 (HO-1) haploinsufficiency impairs
angiogenic potential of bone marrow-derived cells
(BMDCs), but does not affect their proliferation, migra-
tion, and survival under oxidative stress. In diabetic ani-
mals, HO-1 haploinsufficiency leads to down-regulated
expression of proangiogenic genes and to impaired re-
vascularization of ischemic tissue, despite a potent mo-
bilization of bone marrow-derived progenitor cells into
peripheral blood. This indicates that angiogenic response
in situ, but not a mobilization of progenitor cells, is cru-
cial for blood flow recovery in diabetic ischemic muscles.
Application of conditioned media from BMDCs, but not
the cultured cells, efficiently augments muscle reperfu-
sion. In addition, a local injection of BMDCs does not
provide an improvement in the wound-healing model,
possibly due to a very fast elution of the cells.
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FIG. 1. Functional analysis of BMDCs isolated from WT (HO-11/1), HET (HO-11/2), and KO (HO-12/2) mice and
cultured for 9 days under conditions promoting the growth of endothelial cells. Comparison of LG (5 mM) and HG
(33 mM) conditions. Unstimulated cells served as a control. (A) HO-1 protein level in BMDCs. ELISA. (B) Cell apoptosis
after exposure to H2O2 (100 lM, 6 h). Hoechst/7AAD staining analyzed using flow cytometry. (C) Cell apoptosis after
exposure to hemin (50 lM, 6 h). Hoechst/7AAD staining analyzed using flow cytometry. (D) Spontaneous proliferation (G2/
S phase) of BMDCs. Hoechst/pyronin Y staining analyzed using flow cytometry. (E) Spontaneous and EGM CM-induced
migration of BMDCs. Transwell assay followed by crystal violet staining. (F, G) Sprouting of capillaries from the BMDC
spheroids embedded in collagen gel. Morphometry. Quantitative data (F) and representative pictures (G). (H) Formation of
cords by HAECs seeded on Matrigel in conditioned media harvested from BMDCs. Unconditioned medium or EGM CM
medium served as negative and positive control, respectively. *p < 0.05, **p < 0.01, ***p < 0.001 versus control; #p < 0.05,
##p < 0.01, ###p < 0.001 versus WT; $p < 0.05, $$p < 0.01, $$$p < 0.001 versus HET; &&p < 0.01 versus LG. WT, wild type;
HET, heterozygous; KO, knockout; LG, low glucose; HG, high glucose; BMDCs, bone marrow-derived cells; HO-1, heme
oxygenase-1; HAECs, human aortic endothelial cells; EGM, endothelial growth medium; CM, complete medium.
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HO-1 + / - cells was 11%–15% lower than in wild-type
counterparts and was not modified by hyperglycemia (Fig.
1A). To evaluate the potential role of HO-1 in the resistance
of BMDCs to oxidative stress, HO-1 + / + , HO-1 + / - , and
HO-1 - / - cultures were exposed for 6 h to H2O2 (100 lM) or
hemin (50 lM) or both under normoglycemic (5 mM) and
hyperglycemic (33 mM) conditions. The toxic effect of H2O2
was weak (Fig. 1B), but treatment with hemin significantly
increased the number of apoptotic cells in HO-1-deficient
BMDCs (Fig. 1C), which indicates that HO-1 acts as a cy-
toprotective agent, especially against hemin-induced injury.
Hyperglycemia did not affect cell viability (Fig. 1B, C).
Cell cycle analysis revealed that the rate of spontaneous
proliferation (percentage of cells at G2 and S phases) was
lower in HO-1 - / - cultures, and not modified by hypergly-
cemia (Fig. 1D). We did not observe differences in G0 to G1
transition. HO-1-deficient cells also exhibited significantly
weaker migration capacity in control starvation medium, as
well as in response to endothelial growth medium (EGM)
complete medium, containing a mixture of growth factors
(Fig. 1E). Thus, HO-1 deficiency, but not HO-1 haploin-
sufficiency, impairs viability, proliferation, and migration of
BMDCs, features that are important for a proper cell function
within the microenvironment of injured tissue.
HO-1 deficiency weakens angiogenic potential
of BMDCs
To evaluate the angiogenic potential of HO-1 + / + ,
HO-1 + / - , and HO-1 - / - BMDCs, we assessed the sprouting
of capillary-like structures from the BMDC spheroids em-
bedded in collagen gel (Fig. 1F, G). Under normoglycemic
conditions, both HO-1 + / - and HO-1 - / - cells formed shorter
capillaries than their HO-1 + / + counterparts. Surprisingly, the
lengths of HO-1 + / + and HO-1 + / - capillaries were increased
in hyperglycemia. Such an increase was not observed in
HO-1 - / - BMDCs (Fig. 1F, G).
Since proangiogenic bone marrow cells were demon-
strated to facilitate blood vessel formation mainly in a para-
crine manner (45, 56), we plated the human aortic endothelial
cells (HAECs) on Matrigel in conditioned media harvested
from the BMDCs (Fig. 1H). Cells cultured in unconditioned
starvation medium (0.5% fetal bovine serum [FBS]) and
unconditioned EGM complete medium served as a negative
and positive control, respectively. Quantification of the
number of branch points showed that conditioned media
(0.5% FBS) from normoglycemic HO-1 + / + BMDCs in-
creased the formation of cord-like structures to a level which
did not significantly differ from that of the positive control
( p = 0.15). Stimulations with media from normoglycemic
HO-1 + / - or HO-1 - / - BMDCs were weaker ( p = 0.004 or
p = 0.015). Interestingly, media harvested from the BMDCs
cultured in hyperglycemia, regardless of their HO-1 geno-
type, displayed strongly reduced paracrine proangiogenic
potential (Fig. 1H).
HO-1 deficiency influences transcriptome
of cultured BMDCs
To shed light on the possible pathways that are responsible
for different angiogenic potential, we compared the tran-
scriptome of HO-1 + / + and HO-1 - / - BMDCs cultured for
the last 24 h in normoxia or hypoxia (Supplementary Tables 1
and 2; all data will be provided on request). Results of Venn’s
analysis showed that HO-1 deficiency significantly changed
the expression of 40 genes (Fig. 2A), namely 27 genes under
normoxic and 18 genes under hypoxic conditions. Only five
of them were regulated in the same way in both normoxia and
FIG. 2. Transcriptome analysis of BMDCs isolated
from WT (HO-11/1) and KO (HO-12/2) mice and cul-
tured for 9 days under conditions promoting the growth
of endothelial cells. For the previous 24 h, cells were cul-
tured under normoxia (21% O2, 5% CO2) or hypoxia (2% O2,
5% CO2). Microarray analysis. (A) Venn’s diagram summa-
rizing the effect of HO-1 deficiency and hypoxia on BMDC
transcriptome. The upper part demonstrates the number of
genes whose expression was changed in either normoxic or
hypoxic conditions due to HO-1 deletion (22 genes are
changed: 4 up-regulated and 18 down-regulated in KO
BMDCs in normoxic conditions. Thirteen genes are changed:
7 up-regulated and 6 down-regulated in KO BMDCs in hyp-
oxic conditions. Five genes are changed: three up-regulated
and two down-regulated in KO BMDCs regardless of oxygen
concentration). Bottom part shows the number of genes whose
expression was changed in either WT or KO cells in response
to hypoxia (552 genes are changed: 289 up-regulated and 263
down-regulated in WT BMDCs in response to hypoxia. One
hundred forty genes are changed: 77 up-regulated and 63
down-regulated in KO BMDCs in response to hypoxia. Two
hundred thirty-seven genes are changed: 172 up-regulated and
65 down-regulated in both genotypes in response to hypoxia).
(B) Examples of hypoxia-mediated inductions of proangio-
genic genes in WT and KO BMDCs. Dashed line indicates the
control level of gene expression under normoxic conditions.
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hypoxia: kininogen-1 (Kng1) and V-set and immunoglobulin
containing-4 (Vsig4) were down-regulated, while acetyl-
transferase like-1 (Aytl1), WNT1-inducible signaling path-
way protein-1 (Wisp1), and solute carrier family-40 member-1
(Slc40a1) were up-regulated. Thus, in most cases, the effect
of HO-1 deficiency was dependent on the oxygen level.
HO-1 + / + and HO-1 - / - BMDCs differentially expressed
some genes regulating angiogenesis, inflammatory reaction,
proliferation, and apoptosis. Lack of HO-1 was associated
with down-regulation of several proangiogenic genes, such as
cyclin-dependent kinase-5 (Cdk5), activating protein-2 (AP-
2), R-spondin-2 homolog (Rspo2), matrix metalloproteinase-
11 (MMP-11), metallotionein-1, Sca-1 (lymphocyte antigen-6
complex, locus-A [Ly6a]), lymphocyte antigen-6 complex,
locus-C1 (Ly6c), or ceruloplasmin, and up-regulation of
Wisp1, which can exert antiangiogenic effects. In addition,
among the 40 genes influenced by HO-1 deficiency, there
were 9 genes of the WNT pathway, 5 genes associated with
iron metabolism, and genes regulating adipogenesis (12) or
osteogenesis (2) (Supplementary Table 1).
In the next step of transcriptome analysis, we checked the
effect of hypoxia in HO-1 + / + and HO-1 - / - BMDCs. Ac-
cording to Venn’s diagram, 929 genes are differently ex-
pressed under normoxia and hypoxia in HO-1 + / + , HO-1 - / - ,
or in both cell types (Fig. 2A and Supplementary Table 2).
The majority of them (552 genes) changed under hypoxic
conditions only in HO-1 + / + BMDCs, while 140 changed
only in HO-1 - / - cells. Thus, HO-1 deficiency modifies the
response to hypoxia, attenuating the hypoxic induction of
several proangiogenic genes, including growth differentia-
tion factor-15 (GDF-15), VEGF, chemokine receptor-like 2
(CCRL2), chemokine receptor-4 (CXCR-4), chemokine
ligand-1 (CXCL-1), hialuronidase-1 (Hyal1), or annexin-A2
(Anxa2) (Fig. 2B and Supplementary Table 2).
BMDC transplantation improves tissue regeneration
neither in cutaneous wound nor in hind limb
ischemia models
To investigate the influence of HO-1 deficiency on the
regenerative potency of BMDCs, we used two in vivo mod-
els. In the first one, either HO-1 + / + or HO-1 - / - BMDCs
were injected intradermally around the cutaneous wounds in
HO-1 - / - mice, in which the wound-healing process was
previously shown to be impaired (22). We observed much
more HO-1 + / + PKH67-positive BMDCs within the wounds
in comparison to HO-1 - / - cells at day 14 post-injury (Fig.
3A, B). However, there was no statistical difference in the
time course of wound closure between all investigated
groups, including the PBS-treated animals (Fig. 3C).
To determine the real proportion of transplanted cells
surviving after an intradermal injection, we performed an
FIG. 3. Effect of BMDC trans-
plantation on WT (HO-11/1) or
KO (HO-12/2) mice. (A, B)
Number of WT and KO BMDCs
14 days after transplantation
(900,000 cells/mouse) to the
wound bed of KO mice. Quantita-
tive data (A) and representative
pictures (B). (C) Wound closure in
KO mice injected with PBS (con-
trol), WT BMDCs, and KO
BMDCs (900,000 cells/mouse),
presented as a percentage of
wound surface at day 0. Morpho-
metry. (D) Number of WT and KO
male BMDCs after transplantation
(200,000 cells/mouse) into the skin
of female WT mice. Quantitative
data. (E) Blood flow in ischemic
muscle in WT and KO mice in-
jected intravenously with PBS
(control), WT BMDCs, or KO
BMDCs (500,000 cells/mouse).
Laser Doppler analysis. *p < 0.05
KO versus WT, #p < 0.05 versus
day 0. To see this illustration in
color, the reader is referred to the
web version of this article at
www.liebertpub.com/ars
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additional analysis using sex-mismatched transplantation
(male BMDCs transplanted to female skin), followed by
quantitative polymerase chain reaction (PCR) to measure the
level of male sry gene. Number of the surviving cells was
calculated using a standard curve (Supplementary Fig. S2).
The obtained results revealed that about 70% of BMDCs
were eluted from the tissue within 6 h after an injection, re-
gardless of their genotype (Fig. 3D). Next, 70% and 90% of
HO-1 + / + and HO-1 - / - cells, respectively, did not survive
for subsequent 3 days. Importantly, BMDC endurance on day
3 tended to be weakened in case of HO-1 - / - cells
( p = 0.068). Thus, of the 200,000 cells injected, only about
1100 HO-1 + / + BMDCs and 600 HO-1 - / - BMDCs were still
present in the skin 7 days after the injection (Fig. 3D), and 1
week later their number was less than 50, preventing catching
the specific PCR signal.
In another model, mice underwent femoral artery ligation
and were subsequently (next day) intravenously injected with
PBS, HO-1 + / + , or HO-1 - / - BMDCs. Unexpectedly, in wild-
type mice, the adoptive transfer of BMDCs impaired tissue
reperfusion, regardless of cell genotype (Fig. 3E). Measure-
ments performed at day 14 also revealed the impaired blood
flow recovery in HO-1 - / - animals in comparison to wild-
type counterparts. Again, the adoptive transfer of HO-1 + / +
BMDCs did not improve the reperfusion but, instead, appeared
to result in a disadvantageous effect (Fig. 3E). Quantitative
PCR analysis of Sry level after a sex-mismatched intravenous
injection of 500,000 cells was not sensitive enough to de-
tect the injected cells in the injured muscle, either 6 h or at
the later time points, which indicates that the homing of in-
jected BMDCs to the ischemic tissue was weak (data not
shown).
Hyperglycemia affects expression of proangiogenic
genes in HO-1 + / - mice
In the next set of experiments, we investigated whether a
decrease in HO-1 expression may influence revascularization
of ischemic tissue in diabetes. Since HO-1 promoter poly-
morphism in human populations leads to a strong variability
in HO-1 expression and insufficient induction of HO-1 can be
associated with cardiovascular complications in diabetic
patients (11), we decided to perform the study using the more
clinically relevant model of HO-1 + / - instead of HO-1 - / -
mice.
Hyperglycemia in mice was induced by injections of
streptozotocin (STZ), with 100% efficiency of the procedure
in both genotypes. Nevertheless, we observed a significantly
higher mortality of HO-1 + / - mice in comparison to HO-1 + / +
counterparts (42.7% vs. 16.6%, respectively; p < 0.05) 4
weeks after STZ dosing. Interestingly, there were obvious
differences in the expression of proangiogenic genes in the
caput gastrocnemius muscle between the wild-type and
heterozygous animals (Fig. 4A–F). Namely, placental growth
FIG. 4. Expression of proan-
giogenic genes in caput gastroc-
nemius muscle of normoglycemic
(control, ctr) and hyperglycemic
(STZ) WT (HO-11/1) and HET
(HO-11/2) mice. Quantitative
mRNA analysis using qRT-PCR,
EF2 constitutive gene served as an
internal control. (A) PlGF. (B)
CXCR-4. (C) SDF-1. (D) VEGF.
(E) VEGFR-1. (F) VEGFR-2.
*p < 0.05, **p < 0.01 WT versus
HET; $p < 0.05, $$p < 0.01 versus
control. PlGF, placental growth
factor; SDF-1, stromal cell-derived
factor 1; STZ, streptozotocin;
VEGF, vascular endothelial growth
factor; qRT-PCR, quantitative re-
verse transcription-polymerase
chain reaction.
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factor (PlGF) (Fig. 4A) and CXCR-4, the SDF-1 receptor
(Fig. 4B), were up-regulated by STZ-induced hyperglycemia
(in case of PlGF, significantly; in case of CXCR-4, it was a
tendency, p = 0.15) in the HO-1 + / + but not in the HO-1 + / -
individuals. On the other hand, the expression of SDF-1
(Fig. 4C) and VEGF (Fig. 4D) was lower in hyperglycemic
HO-1 + / - individuals in comparison to control HO-1 + / -
mice or to both HO-1 + / + groups, whereas the PlGF and
VEGF receptors (VEGF-R1 and VEGF-R2) were strongly
down-regulated in hyperglycemic groups and in normogly-
cemic HO-1 + / - mice (Fig. 4E, F). Thus, gene expression
analysis may suggest that tissue revascularization might be
impaired in hyperglycemic HO-1 haplodeficient individuals.
Blood flow recovery is impaired in hyperglycemic
HO-1 + / - mice in spite of progenitor cell mobilization
We investigated the mobilization of progenitor cells (Sca-
1 + CXCR-4 + ) into peripheral blood in response to femoral
artery ligation at day 1, 2, and 3 after surgery. Flow cytometry
analysis showed that in wild-type mice, either normogly-
cemic or hyperglycemic induction of hind limb ischemia did
not mobilize Sca-1 + CXCR-4 + cells. In contrast, in HO-1 + / -
counterparts, the same procedure resulted in a significant in-
crease in circulating progenitor cells, especially in hypergly-
cemic individuals, with a peak of mobilization at 24 h after
surgery (Fig. 5A). Accordingly, SDF-1 gradient between is-
chemic muscle and bone marrow, measured at mRNA level,
was the highest in hyperglycemic HO-1+ / - mice (Fig. 5B).
SDF-1 gradient did not correlate with the expression of
HO-1 in the caput gatrocnemius muscle. Concentration of
HO-1 protein in the healthy muscle of HO-1 + / - mice was
lower roughly by 50% in comparison to that of HO-1 + / +
counterpart, and in both groups it was decreased after STZ
treatment (Fig. 5C). Induction of ischemia led to a gradual
increase in HO-1 protein levels, but this effect was significant
only in the hyperglycemic HO-1 + / - mice. Despite this up-
regulation, concentration of HO-1 protein in the muscle
remained lower in the HO-1 + / - mice in comparison to the
HO-1 + / + mice (Fig. 5C).
Thus, HO-1 haploinsufficiency in hyperglycemic mice
diminishes the expression of proangiogenic genes (Fig. 4); on
FIG. 5. Effect of HO-1
haploinsufficiency on pro-
genitor cell mobilization
and blood flow recovery in
mice subjected to hind limb
ischemia. Femoral artery li-
gation was performed in
normoglycemic (control, ctr)
and hyperglycemic (STZ)
WT (HO-1 + / + ) and HET
(HO-1 + / - ) mice. (A) Frac-
tion of progenitor cells (Sca-
1 + CXCR-4 + ) in peripheral
blood before operation or 1,
2, and 3 days after the in-
duction of ischemia. Flow
cytometry phenotyping. (B)
SDF-1 gradient between is-
chemic caput gastrocnemius
muscle and bone marrow
measured at mRNA level.
qRT-PCR. EF2 constitutive
gene served as an internal
control. (C) HO-1 protein
expression in caput gastroc-
nemius muscle. (D, E) Blood
flow recovery in ischemic
muscle. Laser Doppler anal-
ysis. Quantitative data (D)
and representative scans (E).
*p < 0.05, **p < 0.01, and
***p < 0.001 HET versus
WT; #p < 0.05, ##p < 0.01,
and ###p < 0.001 versus day
0; and $p < 0.05 versus nor-
moglycemic counterparts. To
see this illustration in color,
the reader is referred to the
web version of this article at
www.liebertpub.com/ars
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the other hand, it leads to the strongest mobilization of pro-
genitor cells into peripheral blood in response to ischemia
(Fig. 5A). To check which of these two processes is more
significant in tissue regeneration, we investigated blood flow
recovery in HO-1 + / - and HO-1 + / + mice. Laser Doppler
scanning did not reveal any difference between perfusion in
normoglycemic HO-1 heterozygous and normoglycemic
HO-1 wild-type animals at any time point. However, re-
perfusion was significantly impaired at day 28 post-surgery in
hyperglycemic HO-1+ / - animals when compared with hy-
perglycemic HO-1+ / + (Fig. 5D, E). Collectively, these results
show that blood flow recovery is impaired in hyperglycemic
HO-1+ / - despite progenitor cell mobilization.
Cell-free strategy for therapeutic angiogenesis
is an effective way to improve blood flow recovery
Since survival rate of locally injected cells was low (Fig.
3D) and an intravenous injection of BMDCs did not improve
blood flow recovery and even resulted in deleterious effects
(Fig. 3E), we used a cell-free strategy for therapeutic an-
giogenesis in a model of hind limb ischemia. For this pur-
pose, hyperglycemic HO-1 + / - mice, in which tissue
revascularization is impaired (Fig. 5D, E), were subjected to
angiogenic therapy utilizing conditioned EBM-2 media (with
0.5% FBS) either from HO-1 + / + BMDCs or from HO-1 - / -
BMDCs. Unconditioned EBM-2 medium with 0.5% FBS was
used as a control.
Media injections were administered for 3 consecutive days
after femoral artery ligation. Blood flow increased in ische-
mic limbs on day 3 post-surgery in animals treated with
conditioned media in comparison to control group. This ef-
fect was prominent on day 7 (Fig. 6A, B). Although the im-
provement reached higher values in animals injected with
media harvested from HO-1 + / + than HO-1 - / - BMDCs,
these differences were not statistically significant. Interest-
ingly, the number of necrotic incidences (appearance of ne-
crotic toes) was not fully parallel to the measured blood flow.
Namely, 3 days after surgery, the number of necrotic toes
significantly increased in control group ( p < 0.001), showed a
tendency to increase in animals injected with media from
HO-1 - / - BMDCs ( p = 0.051), and did not significantly in-
crease in counterparts injected with HO-1 + / + BMDC-
derived media ( p = 0.485). On day 7, the increase in necrotic
events became significant in all groups; however, the animals
injected with media from HO-1 - / - BMDCs were very sim-
ilar to those injected with control media, whereas there was a
tendency for weaker increase in animals treated with media
from HO-1 + / + BMDCs ( p = 0.086).
Analysis of gene expression revealed the tendency or
significant up-regulation of VEGF, PlGF, and SDF-1 mRNAs
in particular groups at day 7 after surgery (Fig. 7A–C). In-
terestingly, the HO-1 expression also was elevated in all in-
vestigated groups, which was shown at both mRNA (Fig. 7D)
and protein (Fig. 7E) levels. Immunohistochemical staining
for CD31 showed that the number of capillaries was signifi-
cantly augmented in ischemic tissue in animals injected with
HO-1 + / + BMDC-conditioned media (Fig. 7F).
Discussion
Exploitation of autologous patients’ cells, subjected to
ex vivo genetic modification to improve their regenerative
potency, could be a promising strategy for the treatment of
PAD. Hmox1 gene, encoding cytoprotective and proangio-
genic HO-1 enzyme (17), is one of candidates considered for
such therapy.
We found that the lack of HO-1 decreases the number of
EPCs in murine bone marrow, and strongly inhibits the
proangiogenic potential of cultured BMDCs, affecting their
survival under oxidative stress, proliferation, migration,
FIG. 6. Effect of conditioned media harvested from
WT (HO-11/1) or KO (HO-12/2) BMDCs on blood flow
recovery in hyperglycemic HET (HO-11/2) muscle.
Media (30 ll in total) were injected into three sites of is-
chemic caput gastrocnemius muscle of mice subjected to
femoral artery ligation. Injections were performed immedi-
ately after surgery (day 0), on day 1, and on day 2. Un-
conditioned media served as a control. (A, B) Blood flow
recovery in ischemic muscle. Laser Doppler analysis.
Quantitative data (A) and representative scans (B). (C)
Percentage of necrotic toes. *p < 0.05, **p < 0.01, and
***p < 0.001 versus control; #p < 0.05, ##p < 0.01, and
###p < 0.001 versus day 0. To see this illustration in color,
the reader is referred to the web version of this article at
www.liebertpub.com/ars
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formation of capillary-like structures, and release of para-
crine growth factors, although the influence on paracrine
functions seems to be weaker than that on direct vasculogenic
activities. These effects are accompanied by changes in
BMDC transcriptome profile, including the reduced up-
regulation of several proangiogenic genes in response to
hypoxia. In addition, STZ-treated diabetic HO-1 + / - mice
exhibit lower expression of proagiogenic genes and impaired
revascularization of ischemic muscles subjected to hind limb
ischemia, in spite of strong mobilization of bone marrow-
derived proangiogenic progenitors into peripheral blood.
We also observed that the administration of STZ causes a
much higher mortality of HO-1 + / - animals in comparison to
their HO-1 + / + counterparts, with a concomitant down-reg-
ulation of HO-1. Since STZ is nephro- and hepatotoxic (36),
and HO-1 was shown to be protective in these organs (48, 73),
a low level of hyperglycemic HO-1 protein may explain the
increased mortality of HO-1 + / - individuals. Such decreased
expression of HO-1 was also found in db/db mice (22) and in
the Goto-Kakizaki rats (46), as well as in type 2 diabetes
patients (1, 8, 12, 50).
Lack of HO-1 attenuates revascularization in HO-1 - / -
mice (26). Here, we demonstrated that haploinsufficiency of
HO-1 does not influence the recovery of blood flow after hind
limb ischemia in normoglycemic animals, but impairs it in
hyperglycemic individuals. This corresponds to a clinical
FIG. 7. Effect of condi-
tioned media harvested
from WT (HO-11/1) or KO




Media (30 ll in total) were
injected into three sites of
ischemic caput gastrocnemi-
us muscle of mice subjected
to femoral artery ligation.
Injections were performed
immediately after surgery
(day 0), on day 1, and on day
2. (A–D) Expression of
proangiogenic genes on day
7 after surgery. Quantitative
mRNA analysis using qRT-
PCR. EF2 constitutive gene
served as an internal control.
(A) VEGF. (B) PlGF. (C)
SDF-1. (D) HO-1. (E) HO-1
protein expression in caput
gastrocnemius muscle. (F)
Number of capillaries in
control and ischemic muscle
analyzed on day 7 after sur-
gery. CD31 immunohisto-
chemical staining analyzed
using a fluorescence micro-
scope. *p < 0.05 versus con-
trol; #p < 0.05, ##p < 0.01, and
###p < 0.001 versus healthy
muscle. To see this illustra-
tion in color, the reader is
referred to the web version of
this article at www.liebertpub
.com/ars
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situation, as there is no association of PAD occurrence with
Hmox1 promoter polymorphism (58), but less active Hmox1
alleles can increase the risk of coronary adverse events in
diabetic patients (16). Noteworthy, the expression of HO-1
protein was lower by *40% in humans with less active
variants of promoter ( ‡ 29 GT repeats) in comparison to
those with more active ( £ 23 GTs) alleles (16). This indicates
that HO-1 haploinsufficiency in mice is relevant to the di-
versity of HO-1 expression in the human population.
Blood flow recovery in our hyperglycemic wild-type mice
was very effective. This might be astonishing, as some re-
ports show a hyperglycemia-induced impairment in revas-
cularization (9). However, the restoration of perfusion in
STZ-treated mice may depend on the interval between dia-
betes induction and artery ligation (52). When surgery is done
4 weeks after STZ treatment, diabetic mice regenerate as
effectively as normoglycemic animals (52), which has also
been confirmed by the present study. Differently, reperfusion
in hyperglycemic HO-1 + / - mice was both delayed and di-
minished at the endpoint by 40% in comparison to HO-1 + / +
animals. To our knowledge, this is the first report on STZ-
treated HO-1 heterozygous mice. Earlier, Liu et al. showed
that in the wild-type hyperglycemic animals the myocardial
expression of HO-1 was strongly up-regulated in response to
ischemia-reperfusion injury, whereas the lack of HO-1 ex-
acerbates tissue damage (39). An insufficient level of HO-1
might be one of the possible reasons of impaired revascu-
larization in hyperglycemic HO-1 + / - animals.
It has been shown that the transfer of HO-1 transgene into
ischemic muscle diminishes cell apoptosis, induces angio-
genesis, enhances muscle perfusion, and limits autoamputa-
tions in mice and rats (6, 26, 60). In diabetic db/db mice,
adenoviral delivery of HO-1 cDNA facilitates neovascular-
ization and improves wound healing (22). Likewise, in-
tracoronary transfer of HO-1 overexpressing bone marrow
stromal cells increases expression of VEGF as well as cap-
illary and arteriole density in a porcine model of myocardial
ischemia reperfusion (27). Moreover, simultaneous trans-
plantation of VEGF and HO-1 overexpressing cells facili-
tated blood flow recovery and decreased the number of
necrotic incidents (41). These data indicate that in vivo re-
vascularization is dependent on HO-1.
Impaired blood flow recovery in HO-1 + / - hyperglycemic
mice corresponds to down-regulation of proangiogenic genes
in caput gastrocnemius muscle. Only in these animals, the
expressions of all genes tested, namely PlGF, VEGF, SDF-1,
VEGFR-1, VEGFR-2, and CXCR-4, are strongly decreased.
In hyperglycemic HO-1 + / + and normoglycemic HO-1 + / -
animals, which regenerate efficiently, there is a low expres-
sion of VEGFR-2, but VEGF can also bind to neuropilin-1
and influence endothelial cells independently of VEGFR-2
signaling (3).
Many studies have described the beneficial effects of
proangiogenic progenitors in tissue vascularization and re-
generation [reviewed in Asahara et al. (2)]. We investigated
the progenitor cell mobilization into peripheral blood in re-
sponse to femoral artery ligation. Taking into account the
monocytic origin of EPCs and endothelial-monocyte mim-
icry, we focused on Sca-1 + CXCR-4 + cells, especially be-
cause such widely defined populations (e.g., MNCs, CD34 +
cells, CD34 + CD133 + cells), enriched in EPCs, were used
in all clinical trials for the treatment of PAD (30, 33, 62).
Mobilization of Sca-1+CXCR-4+ cells occurs only in HO-1+ / -
mice, and hyperglycemia enhances this process. However,
blood flow recovery is impaired in hyperglycemic individu-
als. Therefore, we suppose that the mobilized cells are dys-
functional and do not contribute to tissue regeneration. They
can be unable to home to injured muscle or can have reduced
regenerative potency, and their release into circulation
can only be a marker of stress reaction. Accordingly,
Sca-1 + CXCR-4 + cells were not mobilized in the effectively
regenerating wild-type animals, although we cannot exclude
that here the mobilization occurred earlier than 24 h after
surgery and, therefore, was not captured in the study. Dis-
pensability of Sca-1 + CXCR-4 + progenitors in blood flow
restoration is in line with the results of the REGENT clinical
trial, where intracoronary infusion of CD34 + CXCR-4 + cells
(analogs of Sca-1 + CXCR-4 + in mice) gave similar results as
unselected bone marrow cells (63).
Interestingly, BMDCs seeded on Matrigel form capillary-
like structures spontaneously, such as endothelial colony-
forming cells (4) or late EPC (47), despite their phenotype
resembling early EPC (47). This indicates that the cell phe-
notype is of secondary importance, and the regenerative po-
tency of progenitors should be assessed in functional tests.
Our in vitro experiments reveal that HO-1 is necessary for
proper activity of BMDCs. As expected (7, 51, 61), HO-1-
deficient BMDCs are less viable when exposed to oxidants or
after transplantation into the wound bed. They also display a
weaker proliferation and migration either in control condi-
tions or in response to growth factors. Similar effects were
observed in murine mature or progenitor endothelial cells
(13, 28) and in human endothelium with less active variants
of Hmox1 promoter (61). We also demonstrated a weaker
angiogenic potency of HO-1 - / - BMDCs in capillary
sprouting assay, confirming the results obtained earlier in
human endothelial cells treated with HO-1 inhibitors (28)
or in murine endothelial cells isolated from HO-1 + / + or
HO-1 - / - mice (13).
Reduced levels of HO-1 in HO-1 + / - BMDCs cultured
under normoglycemic conditions did not significantly affect
cell viability, proliferation, and migration, but impaired an-
giogenic potential (summarized in Fig. 8). We observed such
a limited effect of HO-1 haploinsufficiency in earlier ex-
periments, where wound healing was strongly delayed in
HO-1 - / - animals. In 3-month-old HO-1 + / - mice, this pro-
cess was almost as efficient as in their wild-type counterparts.
In older HO-1 + / - individuals, however, the wound healing
was significantly delayed (22). In current experiments, we
found that hyperglycemia, in addition, reduced migratory
capacities of the HO-1 + / - BMDCs. Our in vitro experiments
also indicate that hyperglycemia does not impair the forma-
tion of capillaries by BMDCs but significantly attenuates
paracrine stimulation of endothelial cells.
In our hands, BMDC transplantation did not influence
tissue regeneration (in a wound-healing model) or caused
even deleterious effects (in hind limb ischemia model). Why
an injection of BMDCs impaired blood flow recovery is not
clear. We cannot exclude the fact that cells formed aggre-
gates which occluded small blood vessels. We injected,
however, only 0.5 · 106 cells, whereas 2 · 106 cells were used
in some earlier experiments (10). Moreover, transplantation
of 105–106 of the cells in murine models investigating ther-
apeutic vascularization seems to be justified as a safe number
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of the cells that are able to promote re-endothelialization/
neovascularization (25, 29, 32, 69, 72). The second pos-
sibility is that an injection of BMDCs, which contain
monocyte-like cells, might lead to an increased inflammatory
reaction. In case of the wound-healing model, lack of effect
of BMDC injection on tissue regeneration might be related to
the very fast clearance of these cells from the skin (*70%
after 6 h, *95% after 3 days, and *99.5% after 7 days). A
small number of HO-1 + / + BMDCs can be recognized in the
sections from the wounds 2 weeks after the injection, whereas
HO-1 - / - cells are almost lacking. Mobilization of the en-
dogenous BMDCs might have also overridden the activity of
exogenously administered cells. However, a similar situation
may occur in patients in whom such an approach might be
tested; hence, we believe that the observations provided here
are of relevance for clinical conditions.
Since postnatal neovascularization is mostly regulated by
paracrine signals (5), we employed a cell-free strategy for the
stimulation of blood flow recovery in ischemic limbs. Such
an approach may have two advantages: It is safer than an
injection of cells (what applies all the more so to cells
transduced ex vivo with viral vectors), and it avoids the
problem of a large number of cells that are needed to be
injected into a patient. Applications of proangiogenic growth
factor cocktails produced ex vivo by the cells have been al-
ready carried out with positive effects (5, 15, 35, 37, 56, 64).
Clinical trials with regard to monotherapy with proangio-
genic proteins were not satisfying (21), and possibly a syn-
ergistic action of growth factors is needed for the formation
of stable blood vessels (15). Our experiments show that an
injection of conditioned media harvested from BMDCs
accelerates the blood flow recovery in ischemic muscles of
diabetic HO-1 + / - mice. The therapeutic effect is clear for
media harvested from both HO-1 + / + and HO-1 - / - BMDCs;
however, those from HO-1 - / - cells tended to be less effi-
cient. A limitation of this study is a lack of a precise
phenotypic characterization of cell population(s) in hetero-
geneous BMDC cultures, which are responsible for this
beneficial effect. Nevertheless, the protocol used enables
obtaining heterogeneous but reproducible cell cultures. We
suppose that augmented angiogenesis not only results from a
direct stimulation of blood vessel formation by growth fac-
tors present in conditioned media, but is also accompanied by
induction of proangiogenic genes at the site of the injection.
Improved blood flow recovery might be also related to the
vasodilatory effect of HO-1-derived CO; however, we did not
observe a significant difference in control limb perfusion
between HO-1+ / + and HO-1- / - hyperglycemic mice, which
suggests that this mechanism does not play a crucial role here.
In summary, we demonstrated that HO-1 is necessary for
proper proangiogenic function of BMDCs. Interestingly,
angiogenic potential is also impaired in HO-1 haploinsuffi-
cient BMDCs. A low level of HO-1 in hyperglycemic mice
leads to worse blood flow recovery in ischemic muscle,
which can be rescued by an injection of conditioned media
from cultured BMDCs, especially from cells with a higher
expression of HO-1.
Materials and Methods
For a more detailed description of methods, please see the
‘‘Supplementary Materials and Methods’’ section.
FIG. 8. Influence of HO-1 haploinsufficiency (HO-11/2) and HO-1 deficiency (HO-12/2) on BMDCs cultured in
normoglycemia and hyperglycemia. Y, inhibition; ____, no effect. Paracrine potential is reduced by hyperglycemia
regardless of HO-1 genotype (indicated by arrow in the box).
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Animals
HO-1 - / - mice, HO-1 + / - mice, and HO-1 + / + littermates
(C57BL/6 · FVB background, 12-week-old males) were used
for all the experiments, except an analysis of EPC in bone
marrow, where 1-year-old animals were employed.
Flow cytometric detection of EPC in bone marrow
Bone marrow cells were collected from tibias and femurs
of adult mice, stained in PBS with 2% FBS for 20 min on ice
with proper antibodies, and analyzed using an LRS II flow
cytometer (BD).
BMDCs isolation and culture
Total bone marrow cells were flashed from tibias and fe-
murs of HO-1 + / + , HO-1 + / - , and HO-1 - / - mice and
centrifuged on Ficoll gradient (400 g, 45 min, room temper-
ature). Buffy coat cells were washed thrice with PBS and
seeded on fibronectin (20 lg/ml) and gelatin (0.25%)-coated
dishes in EGM-2 MV media (EBM-2 with supplement)
containing 10% FBS and 5 mM glucose (LG) or 33 mM
glucose (HG). All experiments were performed in cultures at
a confluence of 90%, 7–10 days after isolation, except the
measurement of proliferation, where cell confluence was
50%. Some cells were incubated for the last 24 h under
hypoxic conditions (2% O2, 5% CO2, LG). To analyze the
acLDL uptake and BS1 binding, the cells were incubated for
2 h in the presence of acLDL-DiI (20 lg/ml) or BS1-FITC
(10 lg/ml) and then inspected under a fluorescence micro-
scope (Nikon Eclipse TX-100).
HAECs culture
Cells were cultured in EGM-2 MV complete medium.
RNA isolation
RNA was isolated from tissues or cultured cells using a
modified acid guanidinium thiocyanate-phenol-chloroform
extraction method, precipitated in isopropanol, washed in
ethanol, dissolved in water, and stored at - 80C.
Transcriptome analysis
Transcriptome of cultured BMDCs was analyzed using
Agilent Whole Mouse Genome Oligo microarrays with
binding sites for 44,000 sequences.
Detection of apoptosis
Cells were washed with PBS, stained with Hoechst 33342
and 7AAD according to the protocol by (59), and analyzed
using an LRS II flow cytometer (BD).
Detection of proliferation
Proliferating cells were analyzed using flow cytometry
after a Hoechst/pyronin Y staining.
Migration assay
Migration was measured using QCM Cell Migration Assay
with inserts of a diameter of 8 lm (Chemicon).
Tube formation on Matrigel
Formation of tubes by HAECs was assayed using growth
factor-reduced Matrigel in 96-well plates.
Spheroid culture assay
Spheroid culture assay was performed as previously de-
scribed (68).
Cell therapy of wounds and ischemic
limbs with BMDCs
For the wound-healing experiment, BMDCs isolated from
HO-1 + / + or HO-1 - / - mice were stained with PKH67. Two
full-thickness excisional wounds were generated on either
side of the dorsal midline of each mouse. Immediately after
injury, 900,000 viable HO-1 + / + or HO-1 - / - cells or PBS
were injected intradermally into four places around the
wound.
For the hind limb ischemia experiment, HO-1 + / + or
HO-1 - / - mice were subjected to femoral artery ligation (49).
PBS or 500,000 BMDCs isolated from HO-1 + / + or HO-1 - / -
individuals were injected intravenously next day after the
surgery.
Cell survival in vivo
Cell survival in vivo was determined after the transplan-
tation of viable cultured BMDCs that were isolated from
HO-1 + / + or HO-1 - / - male mice into the tail vein (500,000
cells/animal) or into healthy skin (200,000 cells/animal) of
HO-1 + / + female mice. The number of cells was quantified by
detecting the male sry gene.
Induction of hyperglycemia
Hyperglycemia was induced by an intraperitoneal injec-
tion of STZ (50 mg/kg of body weight) for 5 consecutive days
in HO-1 + / - and HO-1 + / + mice. Individuals were regarded
as hyperglycemic when fasting blood glucose level exceeded
240 mg/dl (31).
Gene expression analysis in caput gastrocnemius
muscle
Total cellular RNA was isolated from caput gastrocnemius
muscle and reversely transcribed. Gene expression at the
mRNA levels was checked by real-time PCR. Total protein
was isolated from caput gastrocnemius muscle. HO-1 ex-
pression at the protein level was checked by ELISA.
Hind limb ischemia in normoglycemic
and hyperglycemic mice
Four weeks after STZ injections, normoglycemic and hy-
perglycemic mice were anesthetized and subjected to left
femoral artery ligation to induce limb ischemia. The super-
ficial blood flow of the ischemic and contralateral limbs was
measured at day 0, 7, and 28 using a Laser Doppler Perfusion
Imager System (PIM II; Perimed).
Progenitor cell mobilization
Peripheral blood was harvested from vena cava superior.
Cells were stained with proper antibodies and analyzed using
an LSRII cytometer (BD).
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Cell-free therapy of ischemic limbs
BMDCs from HO-1 + / + or HO-1 - / - mice were incubated
in EBM-2 containing 0.5% FBS for 24 h. After this period,
conditioned media were collected. HO-1 + / - STZ-treated
mice (n = 12) were subjected to femoral artery ligation.
Conditioned or control (EBM-2 with 0.5% FBS) media in a
total volume of 30 ll were injected intramuscularly into ca-
put gastrocnemius muscle at days 0, 1, and 2. Blood flow
measurements and necrotic toe assessments were done at
days 0, 3, and 7.
CD31 immunohistochemical staining
Gastrocnemius muscles were excised, embedded in OCT
compound (Tissue-Tek), and snap frozen in liquid nitrogen.
Cryostat sections were stained for CD31 to assess capillary
density.
Statistical analysis
Results are expressed as mean – SEM. In vitro experiments
were repeated at least thrice, while in vivo studies were
performed in six mice per group, unless otherwise indicated.
In the transcriptome study, the results were analyzed using
one-tailed Bayesian ANOVA with post hoc Tukey HSD test,
followed by p correction with Benjamini–Hochberg FDR
test, at FDR < 20%. In the other experiments, the two-tailed
Student’s t-test was used for a comparison of the groups and
the two-tailed Fisher’s exact test was used for a comparison
of proportions.
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